CEO addresses shareholders with update on relisting efforts, pipeline progress, and financial stability
The clinical-stage biotech company developing treatments for diseases with significant unmet medical need Lipella Pharmaceuticals Inc. (OTC: LIPO), is reassuring shareholders of its continued momentum following a recent delisting from the Nasdaq Capital Market.
In a shareholder letter released today, CEO Jonathan Kaufman directly addressed frequently asked questions surrounding the delisting, emphasizing that the company remains operationally sound, clinically focused, and strategically committed to relisting on a national exchange.
“While we are disappointed with Nasdaq’s decision, Lipella’s underlying business remains strong. We are advancing meaningful therapies through the clinical program previously outlined, maintaining full SEC compliance, and actively pursuing relisting,” said Dr. Kaufman. “Our mission, leadership team, and long-term strategy remain unchanged.”
The company confirmed that it is evaluating alternative national exchanges that support early-stage innovators and plans to submit an initial listing application in the near term. In the meantime, Lipella continues to progress its clinical pipeline, with no disruption to staffing or research timelines.
Lipella’s lead programs include LP-310 for oral lichen planus, a chronic inflammatory condition affecting the mucous membranes of the mouth, and LP-10 for hemorrhagic cystitis, a painful bladder condition often caused by cancer therapies. Final topline results from the ongoing Phase 2a trial of LP-310 are expected in the second half of 2025.
The company also highlighted its solid financial footing, noting that it has adequate capital to support current development efforts and is committed to prudent fiscal oversight.
Lipella plans to maintain open communication with its investor base through SEC filings, press releases, and active participation in upcoming investor conferences and calls. The full shareholder letter can be accessed through the company’s latest Form 8-K filing with the U.S. Securities and Exchange Commission.
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn .
This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/
The post Lipella Pharmaceuticals Reaffirms Strategic Vision and Clinical Momentum Following Nasdaq Delisting appeared first on PRISM MarketView.